A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

Suppressed patients with drug-resistant HIV-1 require effective and simple antiretroviral therapy to maintain treatment adherence and viral suppression. This randomized, open-label, noninferiority, multicenter pilot study involved HIV-infected adults who met the following criteria: confirmed HIV-1 R...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Santos, José Ramón, Domingo, Pere, Portilla, Joaquín, Gutiérrez, Félix, Imaz, Arkaitz, Vilchez, Helem, Curran, Adrian, Valcarce-Pardeiro, Nieves, Payeras, Antoni, Bernal, Enrique, Montero-Alonso, Marta, Yzusqui, Miguel, Clotet Sala, Bonaventura, Videla, Sebastià, Moltó, José, Paredes, Roger, Universitat Autònoma de Barcelona
Format: Artikel
Sprache:eng
Schlagworte:
Darunavir/cobicistat
Dolutegravir
Multidrug resistance HIV-1
Switch strategy
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Suppressed patients with drug-resistant HIV-1 require effective and simple antiretroviral therapy to maintain treatment adherence and viral suppression. This randomized, open-label, noninferiority, multicenter pilot study involved HIV-infected adults who met the following criteria: confirmed HIV-1 RNA